Patt Highlights Payer, Education Considerations in Trastuzumab Deruxtecan Use for HER2-Low Breast CancerFebruary 21st 2023
At Patient-Centered Oncology Care®, Debra Patt, MD, PhD, MBA, of Texas Oncology, discussed managed care considerations that arise from the groundbreaking DESTINY-Breast04 study presented earlier this year.
Additional Results From POLARIX Study Show Improved PFS With No Reduction in HRQOLJanuary 29th 2023
New data from the POLARIX STUDY show that substituting polatuzumab vedotin for 1 part of a classic first-line chemotherapy combination to manage diffuse large B-cell lymphoma improved progression-free survival without compromising health-related quality-of-life.
In Community-Based Study, Switching to Ixazomib in Newly Diagnosed MM Brought Improved Responses Across Age GroupsJanuary 25th 2023
An analysis presented during the 64th American Society of Hematology Annual Meeting and Exposition showed that patients with multiple myeloma were able to experience improved responses to the proteasome inhibitor ixazomib after switching from bortezomib.
CARG Chemotherapy Toxicity Tool Helps Patients Understand Risks, Says Dr Alonso V. PachecoJanuary 21st 2023
Patient quality of life can be improved through shared knowledge between doctors and patients in cancer care using the Cancer and Aging Research Group (CARG) Chemotherapy Toxicity Tool calculator, which Rocky Mountain Cancer Centers piloted, explained Alonso V. Pacheco, MD, medical director and medical oncologist/hematologist, Rocky Mountain Cancer Centers.
There Is a Need to Identify Patients Most Likely to Benefit From Immunotherapies, Says Dr Alonso V. PachecoJanuary 17th 2023
New immunotherapies are changing the shape of oncology care, but there is also a need for a system that provides these high-quality therapies to the patients most likely to benefit from them. This might mean doing an assessment and a deeper dive into patient functional status, says Alonso V. Pacheco, MD, medical director and medical oncologist/hematologist, Rocky Mountain Cancer Centers.
Dr Alonso V. Pacheco Discusses a Tool to Measure Chemotherapy Toxicity for Elderly PatientsJanuary 13th 2023
A tool to measure chemotherapy toxicity from the Cancer and Aging Research Group can help determine emergency department visits or hospitalization risk, especially for elderly patients, says Alonso V. Pacheco, MD, medical director and medical oncologist/hematologist, Rocky Mountain Cancer Centers.
Dr Timothy Murphy: Strong Communication Is Necessary for Practices Stocking Multiple BiosimilarsNovember 13th 2022
With multiple biosimilars approved for a reference product and different payers preferring particular products, communication between the clinical pharmacy team and the managed care team is crucial, said Timothy Murphy, MD, FACP, medical oncologist/hematologist with Rocky Mountain Cancer Centers.
Dr Timothy Murphy Discusses Successfully Implementing Biosimilars Into Community Cancer PracticeOctober 28th 2022
Having a plan in place to educate providers and the pharmacy team has contributed to the success that Rocky Mountain Cancer Centers (RMCC) has had with rapidly implementing biosimilars, said Timothy Murphy, MD, medical oncologist/hematologist with RMCC.